$LXRX

LEXICON PHARMACEUTICALS, INC.

Lexicon Pharmaceuticals is a biopharmaceutical company that researches and develops drug candidates and commercializes INPEFA, its approved drug. Its portfolio includes sotagliflozin, which it is developing for hypertrophic cardiomyopathy and type 1 diabetes and commercializing for heart failure; pilavapadin for neuropathic pain; LX9851 for obesity and associated cardiometabolic disorders; and compounds in additional preclinical programs. INPEFA is approved in the United States to reduce certain cardiovascular and heart-failure risks in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors. Lexicon sells INPEFA principally to major and regional wholesalers, which resell it to pharmacies, hospitals and other institutions, and also uses a mail order pharmacy. It earns royalties under licenses for drug development and commercialization, including agreements covering sotagliflozin and LX9851. Lexicon is headquartered in The Woodlands, Texas.

0
1
0
$50K
—
Exton Michael
0%
See all $LXRX insider activity →
Med

Lexicon Pharmaceuticals Sets Sights on Heart Trial Results, Diabetes Drug Resubmission in 2027

Lexicon Pharmaceuticals (LXRX) expects results from a heart trial and plans to resubmit sotagliflozin for type 1 diabetes in Q1 2027. The company aims for FDA approval in 2027, with safety data from the STENO1 study addressing DKA concerns. Lexicon also plans to market the drug for hypertrophic cardiomyopathy (HCM) separately, with its own pricing and branding.

Exton Michael purchased $50K of LXRX

Exton Michael (Chief Executive Officer) purchased 30,064 shares of LEXICON PHARMACEUTICALS, INC. (LXRX) at $1.66 on 2026-11-06.

LXRX sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning LXRX (LEXICON PHARMACEUTICALS, INC.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.

Recent LXRX coverage spans financial news, earnings and insider activity.

In the last 30 days, LXRX insiders filed 1 SEC Form 4 transaction — 1 purchase ($50K) and no sales. The most active reporter was Exton Michael, Chief Executive Officer, with 1 filing.

What's driving LXRX

AlphAI scores every news story that mentions LXRX with an AI model for sentiment and relevance, and aggregates insider trades from LEXICON PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $LXRX

Score

What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call

Lexicon Pharmaceuticals (LXRX) reported Q3 earnings, delaying ZYNQUISTA's diabetes application resubmission to Q1 2027 due to data preparation. The company presented preclinical obesity findings for pilavapadin and received a $10M milestone payment from Novo Nordisk. R&D expenses fell to $16.2M, while cash reserves stood at $183.2M.

Lexicon (LXRX) Q3 2026 Earnings Call Transcript

Lexicon (LXRX) reported Q3 2026 progress, including completion of patient enrollment in the phase III SONATA-HCM study for HCM, with top-line results expected in Q1 2027. The company also made strides in resubmitting the NDA for ZYNQUISTA in type 1 diabetes, supported by new safety data from the STENO1 study, aiming for resubmission in Q1 2027.

$LXRXMedEarnings

LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled…

LEXICON PHARMACEUTICALS, INC. (LXRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LEXICON PHARMACEUTICALS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CLINICAL UPDATES Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resu

$LXRXMedAI 8/10

Lexicon shares baseline data from heart disease drug trial

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported baseline data from its Phase 3 SONATA-HCM trial for sotagliflozin, enrolling 542 patients with hypertrophic cardiomyopathy. The study aims to measure symptom improvement using the KCCQ-CSS score, with topline results expected in Q1 2027. The trial includes patients with non-obstructive and obstructive HCM, with no FDA-approved treatments currently available for the former.

Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today

Lexicon Pharmaceuticals (LXRX) stock rose nearly 6% after Cantor Fitzgerald analyst Steve Seedhouse initiated coverage with an overweight rating and $8 price target, citing potential FDA approval for sotagliflozin in treating hypertrophic cardiomyopathy. The drug is currently in late-stage development for this indication, with Seedhouse noting its unique mechanism could complement existing treatments.

Related tickers